Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Axonics Modulation Technologies, Inc. operates as a medical technology company. The Company focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation solutions which used to treat patients with overactive bladder, fecal incontinence, andurinary retention. Axonics Modulation Technologies serves patients globally.
Website: axonics.com


  • Bad financial results growth rate -12.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (15.6%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -1.3% (LTM)
  • Share price is 47.9% higher than minimum and 0.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (1 502.0x vs 30.0x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: AXNX
Share price, USD:  (0.0%)70.98
year average price 70.98  


year start price 70.98 2025-06-15

max close price 70.98 2025-06-15

min close price 70.98 2025-06-15

current price 70.98 2026-06-14
Common stocks: 45 238 201

Dividend Yield:  0.0%
FCF Yield LTM: -1.3%
EV / LTM EBITDA: 1 502.0x
EV / Sales: 8.8x
Margin (EBITDA LTM / Revenue): 0.6%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 3 211
Net Debt ($m): -207
EV (Enterprise Value): 3 004
EBITDA LTM (млн $): 2
EV / LTM EBITDA: 1 502.0x
Price to Book: 4.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-11-19zacks.com

Boston Scientific Stock Set to Gain From Completion of Axonics Deal

2024-11-15prnewswire.com

Boston Scientific Closes Acquisition of Axonics, Inc.

2024-11-07zacks.com

Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates

2024-09-27zacks.com

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

2024-09-25zacks.com

Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic

2024-08-01zacks.com

Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates

2024-03-29Zacks Investment Research

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

2024-03-15Zacks Investment Research

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

2024-02-28Zacks Investment Research

Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates

2024-01-31Zacks Investment Research

4 Stocks Backed by High Efficiency to Enrich Your Portfolio
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-04-30 2023-10-31 2023-07-31 2023-05-02 2022-11-09
acceptedDate 2024-11-07 16:08:53 2024-08-01 16:07:02 2024-04-30 16:28:58 2024-04-29 16:39:05 2023-10-30 18:17:07 2023-07-31 17:23:01 2023-05-01 21:01:02 2023-03-01 16:24:17 2022-11-09 16:07:51 2022-03-01 17:21:54 2021-03-01 16:55:05 2020-03-04 16:31:31
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
revenue 116M 115M 91M 366M 93M 23M 71M 274M 70M 180M 112M 14M
costOfRevenue 27M 28M 22M 92M 24M 23M 18M 76M 19M 65M 44M 6M
grossProfit 90M 87M 69M 275M 69M 0 53M 198M 51M 116M 67M 7M
grossProfitRatio 0.772 0.758 0.758 0.742 0 0.743 0.728
researchAndDevelopmentExpenses 13M 13M 11M 35M 8M 9M 8M 34M 8M 37M 29M 20M
generalAndAdministrativeExpenses 24M 16M 15M 46M 12M 11M 12M 40M 9M 33M 26M 19M
sellingAndMarketingExpenses 53M 51M 56M 190M 48M 44M 43M 156M 40M 106M 66M 49M
sellingGeneralAndAdministrativeExpenses 77M 68M 71M 235M 59M 55M 55M 196M 49M 139M 92M 68M
otherExpenses 6M 0 0 15M 0 0 2M 9M 2M 7M -412 150 0
operatingExpenses 90M 81M 85M 270M 70M 66M 65M 240M 59M 183M 121M 88M
costAndExpenses 122M 108M 107M 392M 94M 23M 83M 316M 79M 248M 165M 94M
interestIncome 5M 5M 4M 17M 4M 4M 4M 5M 2M 40 000 761 000 3M
interestExpense 0 32 000 59 000 0 83 000 174 000 683 000 2M 2M 7M 2M 2M
depreciationAndAmortization 3M 3M 4M 12M 2M 2M 4M 13M -4M 10M 3M 2M
ebitda 421 000 10M -8M 8M 6M 22M -9M -47M -13M -62M -51M -78M
ebitdaratio 0.004 0.085 -0.09 0.063 0.983 -0.122 -0.178
operatingIncome -6M 6M -19M -26M -687 000 20M -13M -42M -8M -67M -54M -81M
operatingIncomeRatio -0.054 0.055 -0.21 -0.007 0.882 -0.178 -0.116
totalOtherIncomeExpensesNet 5M 5M -4M 17M 4M -16M 3M 3M -9M -7M -1M 665 000
incomeBeforeTax -2M 8M -15M -9M 4M -8M -10M -62M -17M -79M -55M -80M
incomeBeforeTaxRatio -0.013 0.073 -0.167 0.038 -0.337 -0.142 -0.238
incomeTaxExpense -2M 1M 4M -3M -427 000 -8M -807 000 -3M -520 000 782 000 1000 1000
netIncome -21 000 7M -19M -6M 4M -7M -9M -60M -16M -80M -55M -80M
netIncomeRatio -0 0.06 -0.209 0.042 -0.323 -0.131 -0.231
eps -0 0.13 -0.38 -0.12 0.078 -0.15 -0.19 -1.28 -0.34 -1.86 -1.48 -2.8
epsdiluted -0 0.13 -0.38 0.078 -0.15 -0.19 -0.34
weightedAverageShsOut 51M 51M 51M 49M 50M 49M 49M 47M 47M 43M 37M 29M
weightedAverageShsOutDil 51M 51M 51M 49M 50M 49M 49M 47M 47M 43M 37M 29M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-04-29 2023-03-01 2022-03-01 2021-03-01 2020-03-04
fiscalYear 2023 2022 2021 2020 2019
netInterestIncome 17M 3M -7M -1M 665 000
ebit -5M -60M -72M -53M -78M
nonOperatingIncomeExcludingInterest -21M -5M 51 000 -720 000 -3M
netIncomeFromContinuingOperations -6M -60M -80M -55M -80M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -6M -60M -80M -55M -80M
epsDiluted -0.12 -1.28 -1.86 -1.48 -2.8

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-04-30 2023-10-31 2023-07-31 2023-05-02 2022-11-09
acceptedDate 2024-11-07 16:08:53 2024-08-01 16:07:02 2024-04-30 16:28:58 2024-04-29 16:39:05 2023-10-30 18:17:07 2023-07-31 17:23:01 2023-05-01 21:01:02 2023-03-01 16:24:17 2022-11-09 16:07:51 2022-03-01 17:21:54 2021-03-01 16:55:05 2020-03-04 16:31:31
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 239M 169M 233M 105M 147M -3M 240M 239M 241M 221M 241M 171M
shortTermInvestments 106M 175M 100M 240M 197M 186M 117M 118M 109M 0 0 13M
cashAndShortTermInvestments 345M 343M 333M 345M 345M 332M 357M 357M 350M 221M 241M 184M
netReceivables 63M 57M 51M 57M 49M 47M 40M 45M 37M 29M 18M 8M
inventory 114M 105M 93M 80M 75M 70M 66M 56M 58M 65M 63M 16M
otherCurrentAssets 4M 6M 6M 9M 7M 6M 6M 7M 5M 6M 5M 4M
totalCurrentAssets 526M 512M 482M 491M 475M 455M 470M 465M 449M 321M 328M 212M
propertyPlantEquipmentNet 21M 40M 17M 33M 7M 6M 7M 7M 7M 7M 6M 3M
goodwill 105M 99M 99M 99M 95M 99M 97M 94M 87M 106M 0 0
intangibleAssets 78M 76M 78M 81M 80M 86M 86M 86M 82M 106M 196 000 311 000
goodwillAndIntangibleAssets 183M 175M 177M 181M 176M 99M 182M 181M 169M 212M 196 000 311 000
longTermInvestments 0 19M 16M 0 0 0 0 0 0 0 0 0
taxAssets 0 0 -16M 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 45M 2M 40M 14M 3M -4M 7M 7M 7M 8M 8M 5M
totalNonCurrentAssets 248M 235M 234M 229M 185M 102M 196M 194M 183M 227M 14M 8M
otherAssets 0 0 0 0 0 92M 0 0 0 0 0 0
totalAssets 774M 747M 716M 720M 661M 649M 666M 659M 632M 548M 342M 220M
accountPayables 20M 19M 16M 18M 15M 12M 15M 9M 10M 8M 11M 6M
shortTermDebt 3M 2M 1M 2M 2M 2M 2M 2M 2M 1M 22M 602 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 42M 36M 31M 13M 19M 18M 50M 38M 49M 11M 5M 3M
totalCurrentLiabilities 64M 57M 48M 46M 36M 32M 66M 65M 61M 27M 46M 12M
longTermDebt 30M 30M 30M 0 876 000 1M 7M 0 8M 0 0 20M
deferredRevenueNonCurrent 0 0 -10M 0 -14M -14M 0 -16M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 15M 16M 10M 11M 14M 15M 16M 16M 14M 19M 0 0
otherNonCurrentLiabilities 0 0 10M 0 14M -1M 0 16M 10M 10M 0 0
totalNonCurrentLiabilities 45M 47M 40M 37M 15M 1M 23M 24M 22M 39M 9M 25M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 33M 32M 32M 28M 3M 3M 9M 9M 9M 10M 10M 5M
totalLiabilities 110M 104M 88M 82M 50M 33M 89M 89M 83M 66M 55M 37M
preferredStock 0 0 0 0 0 373M 0 0 0 0 0 0
commonStock 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 4000 3000
retainedEarnings -393M -393M -399M -380M -387M -391M -384M -374M -375M -315M -234M -180M
accumulatedOtherComprehensiveIncomeLoss -6M -17M -17M -16M -25M -18M -22M -25M -36M -7M -431 000 -428 000
othertotalStockholdersEquity 1 063M 1 052M 1 044M 1 022M 18M 982M 961M
totalStockholdersEquity 664M 643M 627M 638M 611M -18M 577M 570M 550M 482M 287M 183M
totalEquity 664M 643M 627M 638M 611M -18M 577M 570M 550M 482M 287M 183M
totalLiabilitiesAndStockholdersEquity 774M 747M 716M 661M 649M 666M 632M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 774M 747M 716M 720M 661M 649M 666M 659M 632M 548M 342M 220M
totalInvestments 106M 193M 100M 240M 197M 186M 117M 118M 109M 0 0 13M
totalDebt 33M 32M 32M 28M 3M 3M 9M 9M 9M 10M 33M 25M
netDebt -207M -136M -201M -77M -144M 6M -231M -230M -232M -210M -208M -146M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-04-29 2023-03-01 2022-03-01 2021-03-01 2020-03-04
fiscalYear 2023 2022 2021 2020 2019
accountsReceivables 57M 45M 29M 18M 8M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 18M 9M 8M 11M 6M
otherPayables 0 0 0 0 0
accruedExpenses 11M 15M 5M 6M 2M
capitalLeaseObligationsCurrent 2M 2M 1M 1M 602 000
capitalLeaseObligationsNonCurrent 26M 8M 9M 9M 4M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 034M 970M 804M 522M 363M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX AXNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-04-30 2023-10-31 2023-07-31 2023-05-02 2022-11-09
acceptedDate 2024-11-07 16:08:53 2024-08-01 16:07:02 2024-04-30 16:28:58 2024-04-29 16:39:05 2023-10-30 18:17:07 2023-07-31 17:23:01 2023-05-01 21:01:02 2023-03-01 16:24:17 2022-11-09 16:07:51 2022-03-01 17:21:54 2021-03-01 16:55:05 2020-03-04 16:31:31
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -21 000 7M -19M -6M 4M -7M -9M -60M -16M -80M -55M -80M
depreciationAndAmortization 3M 3M 3M 13M 3M 3M 3M 12M 3M 9M 2M 1M
deferredIncomeTax -2M 8M -2M -7M -988 000 -516 000 -1M -184 000 8000 582 000 431 000 75 000
stockBasedCompensation 8M 9M 10M 45M 11M 11M 11M 32M 8M 25M 15M 9M
changeInWorkingCapital -9M -12M -3M -66M -5M -42M -6M -3M 9M -10M -47M -14M
accountsReceivables -5M -7M 6M -12M -2M -7M 5M -16M -960 000 -9M -11M -8M
inventory -8M -15M -14M -26M -5M -4M -10M 8M 36 000 -1M -47M -12M
accountsPayables 675 000 4M -3M 9M 3M -3M 6M 1M 364 000 -3M 5M 2M
otherWorkingCapital 4M 6M 1M -37M -1M -28M -6M 3M 10M 3M 6M 3M
otherNonCashItems 708 000 36M 1M 19M 13 000 16M 2M 22M -8000 8M 939 000 873 000
netCashProvidedByOperatingActivities 922 000 17M -9M -2M 12M -19M -781 000 3M 4M -47M -84M -83M
investmentsInPropertyPlantAndEquipment -3M -1M -3M -4M -1M -256 000 -794 000 -2M -963 000 -2M -3M -1M
acquisitionsNet 0 0 0 0 10M 68M 0 56M 0 -141M 0 -47M
purchasesOfInvestments -69M -143M -28M -427M -114M -122M -52M -175M -118M 0 0 -36M
salesMaturitiesOfInvestments 143M 67M 169M 313M 104M 54M 54M 57M 20M 0 13M 83M
otherInvestingActivites 0 -76M 141M -10M -68M 0 0
netCashUsedForInvestingActivites 70M -77M 138M -11M -69M 694 000 -99M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued -489 000 241 000 248 000 878 000 864 000 2M 128M
commonStockRepurchased 0 0 0 15M 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 3M 241 000 248 000 878 000 -8M 0 3M
netCashUsedProvidedByFinancingActivities 3M 241 000 248 000 878 000 -7M 2M 132M
effectOfForexChangesOnCash 710 000 -1M 2M 979 000 -189 000 -164 000 -584 000 1M 2M -508 000 -3000 -12 000
netChangeInCash 93M -64M 131M -121M 2M -95M 1M 18M 38M -20M 70M 73M
cashAtEndOfPeriod 262M 169M 248M 118M 147M 145M 240M 239M 241M 221M 241M 171M
cashAtBeginningOfPeriod 169M 233M 118M 239M 145M 240M 239M 221M 203M 241M 171M 98M
operatingCashFlow 922 000 17M -9M -2M 12M -19M -781 000 3M 4M -47M -84M -83M
capitalExpenditure -3M -1M -3M -4M -1M -256 000 -794 000 -2M -963 000 -2M -3M -1M
freeCashFlow -2M 16M -12M -6M 11M -19M -2M 968 000 3M -50M -87M -85M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-04-29 2023-03-01 2022-03-01 2021-03-01 2020-03-04
fiscalYear 2023 2022 2021 2020 2019
otherInvestingActivities 0 -56M 0 13M 47M
netCashProvidedByInvestingActivities -117M -120M -143M 10M 45M
netDebtIssuance 0 0 -26M 0 0
longTermNetDebtIssuance 0 0 -26M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 128M 201M 150M 118M
netCommonStockIssuance 0 128M 201M 150M 118M
commonStockIssuance 4M 128M 201M 150M 118M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -3M 5M -5M -5M -7M
netCashProvidedByFinancingActivities -3M 134M 171M 144M 111M
incomeTaxesPaid 255 000 667 000 1000 1000 1000
interestPaid 69 000 1000 2M 1M 1M

Earning call transcript

2023 q3
2023-10-30 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-01 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-09-26 10:00 ET
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
2024-09-18 22:59 ET
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
2024-08-01 20:01 ET
Axonics Reports Second Quarter 2024 Financial Results
2024-07-25 12:00 ET
Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors
2024-05-16 20:01 ET
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
2024-04-30 20:01 ET
Axonics Reports First Quarter 2024 Financial Results
2024-03-21 20:54 ET
Axonics Provides Update on Inter Partes Review Proceedings
2024-03-14 10:00 ET
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
2024-02-29 21:01 ET
Axonics Responds to ITC Action by Medtronic
2024-02-28 21:01 ET
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
2024-01-31 11:30 ET
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
2024-01-08 13:47 ET
AXNX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Axonics to Boston Scientific
2024-01-08 12:00 ET
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
2024-01-08 12:00 ET
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
2024-01-08 12:00 ET
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
2023-12-27 21:01 ET
Axonics to Present at the J.P. Morgan Healthcare Conference
2023-12-27 13:00 ET
BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors
2023-11-01 10:00 ET
Axonics to Participate in November Investor Conferences
2023-10-30 20:01 ET
Axonics Reports Third Quarter 2023 Financial Results
2023-10-02 10:00 ET
Axonics to Report Third Quarter 2023 Financial Results on October 30
2023-08-25 10:00 ET
Axonics to Participate in September Investor Conferences
2023-08-21 10:00 ET
Axonics Announces CFO Retirement and Appoints Successor
2023-07-27 20:01 ET
Axonics Reports Second Quarter 2023 Financial Results
2023-06-29 10:00 ET
Axonics to Report Second Quarter 2023 Financial Results on July 27
2023-05-01 20:01 ET
Axonics Reports First Quarter 2023 Financial Results
2023-04-25 10:00 ET
Axonics to Participate in Upcoming Investor Conferences
2023-04-24 10:00 ET
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
2023-04-10 10:00 ET
Axonics to Report First Quarter 2023 Financial Results on May 1
2023-03-29 10:00 ET
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
2023-03-07 11:00 ET
Axonics to Participate in the SUFU 2023 Winter Meeting
2023-03-01 21:01 ET
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2023-02-08 21:30 ET
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
2023-01-31 11:00 ET
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
2023-01-11 11:00 ET
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
2022-12-21 11:00 ET
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-13 11:00 ET
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
2022-11-18 11:00 ET
Axonics® to Participate in the Piper Sandler Healthcare Conference
2022-11-16 16:06 ET
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
2022-10-31 20:01 ET
Axonics® Reports Third Quarter 2022 Financial Results
2022-10-10 10:00 ET
Axonics® to Report Third Quarter 2022 Financial Results on October 31
2022-09-08 10:00 ET
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
2022-08-18 10:00 ET
Axonics® to Participate in September Investor Conferences
2022-08-17 10:00 ET
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
2022-08-05 20:34 ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
2022-08-03 03:13 ET
Axonics® Announces Pricing of Public Offering of Common Stock
2022-08-02 20:11 ET
Axonics® Announces Proposed Public Offering of Common Stock
2022-08-01 20:01 ET
Axonics® Reports Second Quarter 2022 Financial Results
2022-07-11 10:00 ET
Axonics® to Report Second Quarter 2022 Financial Results on August 1
2022-05-31 10:00 ET
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
2022-05-05 20:01 ET
Axonics® Reports First Quarter 2022 Financial Results
2022-04-26 10:00 ET
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
2022-04-19 10:00 ET
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
2022-04-14 20:01 ET
Axonics® to Report First Quarter 2022 Financial Results on May 5
2022-04-04 10:00 ET
Axonics® Launches Direct to Consumer Television Advertising Campaign
2022-03-07 21:01 ET
Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System
2022-02-24 21:01 ET
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
2022-02-03 11:00 ET
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
2022-02-01 11:00 ET
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
2022-01-25 11:00 ET
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
2022-01-06 11:00 ET
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
2021-11-30 11:00 ET
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council
2021-11-17 11:00 ET
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
2021-11-17 10:01 ET
Deloitte Unveils 2021 North America Technology Fast 500 Rankings
2021-11-08 11:00 ET
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
2021-11-04 20:01 ET
Axonics® Reports Third Quarter 2021 Financial Results
2021-10-26 10:00 ET
Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
2021-10-07 11:00 ET
Axonics® to Report Third Quarter 2021 Financial Results on November 4
2021-09-22 22:08 ET
Axonics® Provides Additional Update on Inter Partes Review Proceedings
2021-09-13 21:29 ET
U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents
2021-09-13 21:19 ET
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
2021-08-27 10:00 ET
Axonics® to Participate in Upcoming Investor Conferences
2021-08-05 20:01 ET
Axonics® Reports Second Quarter 2021 Financial Results
2021-07-21 11:30 ET
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors
2021-07-15 10:00 ET
Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors
2021-07-08 10:00 ET
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
2021-06-24 20:01 ET
Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator
2021-05-20 10:00 ET
Axonics® Receives FDA Approval Further Expanding MRI Labeling
2021-05-18 13:00 ET
Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval
2021-05-14 20:05 ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
2021-05-12 02:55 ET
Axonics® Announces Upsize and Pricing of Public Offering of Common Stock
2021-05-11 20:17 ET
Axonics® Announces Proposed Public Offering of Common Stock
2021-05-06 20:01 ET
Axonics® Reports First Quarter 2021 Financial Results
2021-04-22 10:00 ET
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference
2021-04-15 10:00 ET
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
2021-03-03 11:00 ET
Axonics® to Participate in the Barclays Global Healthcare Conference
2021-03-02 12:55 ET
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
2021-03-02 11:00 ET
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device
2021-02-25 21:05 ET
Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
2021-02-25 21:01 ET
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®
2021-02-22 21:01 ET
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021
2021-02-18 11:00 ET
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting
2021-02-16 11:00 ET
Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator
2021-02-11 11:00 ET
Axonics® to Participate in the SVB Leerink Global Healthcare Conference
2021-01-25 21:01 ET
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
2020-12-14 13:00 ET
Axonics® Announces Appointment of David M. Demski to Board of Directors
2020-11-19 11:00 ET
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
2020-11-10 11:00 ET
Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System
2020-11-04 21:00 ET
Axonics® Reports Third Quarter 2020 Results
2020-10-29 10:00 ET
Axonics® Submits PMA Supplement to FDA to Further Expand MRI Labeling
2020-10-20 12:00 ET
Axonics® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System
2020-10-14 10:00 ET
Axonics® to Report Third Quarter 2020 Results on November 4
2020-10-07 20:00 ET
Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Winner for Orange County
2020-10-05 12:00 ET
Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
2020-09-24 10:00 ET
 Axonics® Provides Update on Inter Partes Review Proceedings
2020-09-21 10:00 ET
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
2020-09-16 13:00 ET
Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Finalist for Orange County
2020-09-10 10:00 ET
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
2020-09-08 12:30 ET
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
2020-09-03 10:00 ET
Axonics® to Participate in Upcoming Investor Conferences
2020-09-02 14:00 ET
Axonics® to Host Presentation of Full 2-Year Clinical Results from ARTISAN-SNM Pivotal Study on September 9
2020-08-06 20:00 ET
Axonics® Reports Second Quarter 2020 Results
2020-07-27 10:00 ET
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
2020-07-16 10:00 ET
Axonics® to Report Second Quarter 2020 Results on August 6
2020-07-13 10:00 ET
Axonics® Reports Preliminary Second Quarter 2020 Revenue
2020-07-01 20:00 ET
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
2020-05-19 10:00 ET
Axonics® ARTISAN Results Published Demonstrating Continued Therapy Response and Patient Satisfaction at 1-year
2020-05-12 20:05 ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
2020-05-08 01:14 ET
Axonics® Announces Pricing of Public Offering of Common Stock
2020-05-07 20:12 ET
Axonics® Announces Proposed Public Offering of Common Stock
2020-05-05 20:00 ET
Axonics® Reports First Quarter 2020 Results
2020-04-29 10:00 ET
Axonics® Names Michael H. Carrel as Chairman of its Board of Directors
2020-04-14 10:00 ET
Axonics® Announces U.S. Food & Drug Administration Approval of Next Generation Implantable Neurostimulator
2020-04-08 10:00 ET
Axonics® to Present at the Needham Healthcare Conference
2020-04-07 10:00 ET
Axonics® to Report First Quarter 2020 Financial Results on May 5
2020-04-06 10:00 ET
Axonics® Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans
2020-03-16 10:00 ET
Axonics® Announces Filing of Petitions Before the United States Patent and Trademark Office Contesting the Validity of Medtronic Patents
2020-03-04 21:01 ET
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
2020-02-25 11:00 ET
Axonics® to Present at the Barclays Global Healthcare Conference
2020-02-19 11:00 ET
Axonics® to Report 2019 Fourth Quarter and Full-Year Financial Results and Host a Conference Call on March 4
2020-02-11 11:00 ET
Axonics® to Present at the SVB Leerink Global Healthcare Conference
2020-02-04 11:00 ET
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
2020-01-21 11:00 ET
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
2020-01-09 11:00 ET
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
2019-12-19 11:00 ET
Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology
2019-12-12 11:00 ET
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
2019-12-09 11:00 ET
Axonics® Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM® System
2019-12-02 11:00 ET
Health Canada Approves Full-Body MRI Labeling for the Axonics® Sacral Neuromodulation System
2019-11-26 11:00 ET
Axonics® to Present at Upcoming Investor Conferences
2019-11-25 11:00 ET
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
2019-11-22 21:24 ET
Axonics® Announces Closing of $110 Million Public Offering of Common Stock
2019-11-21 11:00 ET
Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical Center
2019-11-20 02:15 ET
Axonics® Announces Pricing of Public Offering of Common Stock
2019-11-19 21:01 ET
Axonics® Announces Proposed Public Offering of Common Stock
2019-11-14 21:00 ET
Axonics® Announces Third Quarter 2019 Financial Results and Operational Update
2019-11-14 11:00 ET
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications
2019-11-07 11:00 ET
Axonics® to Report 2019 Third Quarter and Nine-Month Financial Results and Host a Conference Call on November 14
2019-11-05 11:00 ET
Axonics® Responds to Patent Action by Medtronic
2019-11-01 14:36 ET
Axonics® Announces First Commercial U.S. Patient Implanted with its Sacral Neuromodulation System
2019-10-15 10:00 ET
Axonics® Provides Update on U.S. Launch Activities
2019-10-07 10:00 ET
Axonics® Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway
2019-10-03 10:00 ET
Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting
2019-10-02 10:00 ET
Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group
2019-09-24 10:00 ET
Axonics® to Exhibit its Sacral Neuromodulation System at the AUGS/IUGA Joint Scientific Meeting on September 24 – 28 in Nashville
2019-09-09 10:00 ET
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
2019-08-01 10:00 ET
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study

SEC forms

Show financial reports only

SEC form 10
2024-11-07 16:08 ET
Axonics Modulation Technologie reported for 2024 q3
SEC form 8
2024-11-07 16:03 ET
Axonics Modulation Technologie reported for 2024 q3
SEC form 8
2024-11-07 16:03 ET
Axonics Modulation Technologie published news for 2024 q3
SEC form 10
2024-08-01 16:07 ET
Axonics Modulation Technologie published news for 2024 q2
SEC form 8
2024-08-01 00:00 ET
Axonics Modulation Technologie published news for 2024 q2
SEC form 8
2024-08-01 00:00 ET
Axonics Modulation Technologie published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Axonics Modulation Technologie reported for 2024 q2
SEC form 10
2024-04-30 16:28 ET
Axonics Modulation Technologie published news for 2024 q1
SEC form 8
2024-04-30 16:09 ET
Axonics Modulation Technologie reported for 2024 q1
SEC form 8
2024-04-30 16:09 ET
Axonics Modulation Technologie published news for 2024 q1
SEC form 10
2024-04-30 00:00 ET
Axonics Modulation Technologie published news for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 10
2024-02-28 20:36 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Axonics Modulation Technologie reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Axonics Modulation Technologie published news for 2023 q4
SEC form 10
2023-10-31 00:00 ET
Axonics Modulation Technologie published news for 2023 q3
SEC form 10
2023-10-30 18:17 ET
Axonics Modulation Technologie published news for 2023 q3
SEC form 8
2023-10-30 16:06 ET
Axonics Modulation Technologie reported for 2023 q3
SEC form 10
2023-07-31 00:00 ET
Axonics Modulation Technologie published news for 2023 q2
SEC form 6
2023-07-27 16:05 ET
Axonics Modulation Technologie reported for 2023 q2
SEC form 8
2023-07-27 00:00 ET
Axonics Modulation Technologie published news for 2023 q2
SEC form 6
2023-06-27 16:06 ET
Axonics Modulation Technologie published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Axonics Modulation Technologie published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Axonics Modulation Technologie published news for 2023 q1
SEC form 8
2023-03-01 00:00 ET
Axonics Modulation Technologie reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Axonics Modulation Technologie reported for 2022 q4
SEC form 8
2023-01-11 00:00 ET
Axonics Modulation Technologie published news for 2022 q4
SEC form 10
2022-11-09 00:00 ET
Axonics Modulation Technologie reported for 2022 q3
SEC form 8
2022-10-31 00:00 ET
Axonics Modulation Technologie reported for 2022 q3
SEC form 8
2022-08-01 00:00 ET
Axonics Modulation Technologie reported for 2022 q2
SEC form 10
2022-08-01 00:00 ET
Axonics Modulation Technologie reported for 2022 q2
SEC form 8
2022-05-05 00:00 ET
Axonics Modulation Technologie reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Axonics Modulation Technologie reported for 2022 q1
SEC form 10
2022-03-01 00:00 ET
Axonics Modulation Technologie published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Axonics Modulation Technologie published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Axonics Modulation Technologie published news for 2021 q4
SEC form 8
2021-11-04 00:00 ET
Axonics Modulation Technologie published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Axonics Modulation Technologie published news for 2021 q3
SEC form 8
2021-08-05 00:00 ET
Axonics Modulation Technologie published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Axonics Modulation Technologie published news for 2021 q2
SEC form 8
2021-05-06 00:00 ET
Axonics Modulation Technologie published news for 2021 q1